Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock? [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
Jazz Pharmaceuticals (JAZZ) has a P/S ratio of 1.78, which is lower than its industry average of 2.87. This suggests that JAZZ is undervalued compared to its peers. (Source: Zacks) Jazz Pharmaceuticals (JAZZ) has a PEG ratio of 0.80, which is lower than its industry average of 2.21. This suggests that JAZZ is undervalued compared to its peers. (Source: Zacks) Jazz Pharmaceuticals (JAZZ) is currently sporting a Zacks Rank of #2 (Buy), which means that the stock is expected to outperform the market and is a good investment opportunity for investors. (Source: Zacks) Jazz Pharmaceuticals (JAZZ) is considered a strong value stock because it has a high Zacks Rank, a low PEG ratio, a low P/S ratio, and a low P/CF ratio, all of which suggest that the stock is undervalued. Additionally, the company has a strong earnings outlook, which makes it an attractive investment opportunity. (Source: Zacks) Here at Zacks, we focus on our proven ranking system, which places an emphasis on earning
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.MarketBeat
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock, down previously from $166.00.MarketBeat
- FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 11/6/24 - Beat
JAZZ
Sec Filings
- 11/21/24 - Form 8-K
- 11/13/24 - Form 4
- 11/12/24 - Form SC
- JAZZ's page on the SEC website